Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-based antifungal agents: current status.

S Arikan1, J H Rex

  • 1Mycology Unit, Department of Microbiology and Clinical Microbiology, Hacettepe University Medical School, Ankara, 06100, Turkey.

Current Pharmaceutical Design
|March 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.

npj antimicrobials and resistance·2026
Same author

<i>In Vivo</i> Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.

Antimicrobial agents and chemotherapy·2021
Same author

The role of miRNAs targeting K-ras and APC genes in colorectal cancer.

Bratislavske lekarske listy·2020
Same author

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Antimicrobial agents and chemotherapy·2019
Same author

Efficacy of Olorofim (F901318) against <i>Aspergillus fumigatus</i>, <i>A. nidulans</i>, and <i>A. tanneri</i> in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.

Antimicrobial agents and chemotherapy·2019
Same author

Genetic origin of Behçet's disease population in Denizli, Turkey; population genetics data analysis; historical demography and geographical perspectives based on β-globin gene cluster haplotype variation.

Genes and immunity·2016
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Lipid-based antifungal formulations improve treatment for immunocompromised patients. These advanced therapies maintain antifungal activity while significantly reducing toxicity, offering new hope for managing invasive fungal infections.

Area of Science:

  • Pharmacology
  • Mycology
  • Drug Delivery Systems

Background:

  • Invasive fungal infections pose a significant threat to immunocompromised patients, characterized by diagnostic challenges and high mortality rates.
  • Limited antifungal agents and their inherent toxicity complicate treatment strategies for these vulnerable populations.

Purpose of the Study:

  • To review the advancements in lipid-based formulations of antifungal agents.
  • To highlight the therapeutic benefits of these novel drug delivery systems in managing invasive fungal infections.

Main Methods:

  • Review of existing literature on lipid-based antifungal formulations.
  • Analysis of clinical data for lipid-based amphotericin B preparations (ABLC, ABCD, AmBisome).
  • Examination of emerging liposomal formulations including nystatin, hamycin, miconazole, and ketoconazole.

Related Experiment Videos

Main Results:

  • Lipid-based amphotericin B formulations demonstrate maintained antifungal efficacy with reduced toxicity compared to conventional forms.
  • Liposomal nystatin is under development with promising preliminary data.
  • Experimental lipid-based formulations of hamycin, miconazole, and ketoconazole show potential.

Conclusions:

  • Lipid formulations represent a significant advancement in antifungal therapy, improving patient outcomes.
  • Technological progress in liposomes and lipid formulations offers promising new strategies for invasive fungal infection management.